Algorithmic fairness in artificial intelligence for medicine and healthcare
In healthcare, the development and deployment of insufficiently fair systems of artificial
intelligence (AI) can undermine the delivery of equitable care. Assessments of AI models …
intelligence (AI) can undermine the delivery of equitable care. Assessments of AI models …
Immune checkpoint inhibitors in cancer therapy
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
Non‐small cell lung cancer in China
P Chen, Y Liu, Y Wen, C Zhou - Cancer Communications, 2022 - Wiley Online Library
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …
First-line immunotherapy for non–small-cell lung cancer
For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …
been characterized by critical progress that has contributed to substantially improved …
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and …
Background Targeted inhibition of the PD-L1–PD-1 pathway might be further amplified
through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune …
through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune …
Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON …
ML Johnson, BC Cho, A Luft… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus
durvalumab and chemotherapy (T+ D+ CT) and durvalumab plus chemotherapy (D+ CT) …
durvalumab and chemotherapy (T+ D+ CT) and durvalumab plus chemotherapy (D+ CT) …
Toward personalized treatment approaches for non-small-cell lung cancer
M Wang, RS Herbst, C Boshoff - Nature medicine, 2021 - nature.com
Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
M Gogishvili, T Melkadze, T Makharadze… - Nature medicine, 2022 - nature.com
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
[HTML][HTML] Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …